Consillium buys majority stake in BioVendor, leading to exit of Accession Mezzanine Capital
Pondělí, 10. červenec, 2017
Patří do kategorie: Novinky
Zdroj: Mezzanine Management GmbH
BioVendor – Laboratorní medicína a.s. („BioVendor”), based in Brno, Czech Republic, is a leader in the production and distribution of in-vitro diagnostic products in Central and Eastern Europe (“CEE”) with an increasing footprint globally.
In June 2017, Consillium a.s. concluded a significant investment for a majority stake in BioVendor, with a view to partnering with the founder and CEO, Dr. Ruzicka, for the accelerated expansion of the group.
At the same time, the transaction led to the exit of Accession Mezzanine Capital III L.P. (“AMC”), a CEE focused investment fund advised by Mezzanine Management.
AMC invested over €8 million into BioVendor since January 2014 by way of non-amortising subordinated loans and supported it in 8 acquisitions, in Germany, Austria, UK, Czech Republic and Slovakia to increase geographical presence and cross-sell own products and services. Throughout its investment period BioVendor has also invested heavily in the in-house development of several new products and technologies.
Chris Buckle, Managing Partner of Mezzanine Management stated that “we are proud to have partnered with BioVendor during this period of rapid growth. It is an excellent company with a broad range of quality products, both equipment and consumables, for the in-vitro diagnostics market. Dr. Ruzicka has the market and technology insight to keep BioVendor at the leading edge in this rapidly developing industry. We have played our role in helping to increase turnover, profit and the breadth of operations, and are now happy to hand over to Consillium to lead the next stage of development”.